FGFR1 Amplification in Breast Cancer
Author Information
Author(s): Elbauomy Elsheikh, Andrew R Green, Maryou BK Lambros, Nicholas C Turner, Matthew J Grainge, Des Powe, Ian O Ellis, Jorge S Reis-Filho
Primary Institution: Nottingham University Hospitals Trust and University of Nottingham
Hypothesis
Does FGFR1 amplification correlate with clinical outcomes in breast cancer?
Conclusion
FGFR1 amplification is found in 8.7% of breast cancers and is an independent predictor of overall survival.
Supporting Evidence
- FGFR1 amplification was observed in 8.7% of the tumors.
- FGFR1 amplification was significantly more prevalent in patients over 50 years of age.
- FGFR1 amplification was the strongest independent predictor of poor outcome in estrogen-receptor-positive tumors.
Takeaway
Some breast cancers have a change in a gene called FGFR1, which can make them harder to treat, especially in older patients.
Methodology
FGFR1 amplification was analyzed in tissue microarrays of 880 breast tumors using chromogenic in situ hybridization.
Limitations
The study did not correlate FGFR1 amplification with protein expression due to antibody optimization issues.
Participant Demographics
Cohort included unselected breast tumors from patients presenting between 1986 and 1998.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website